๐Ÿ›๐•ฃ๐•• ๐•ช๐•–๐•’๐•ฃ ๐•Ÿ๐• ๐•ฅ๐•–๐•ค ~๐Ÿ—’
457 subscribers
169 photos
62 files
2 links
ู…ู„ุฎุตุงุช ุณู†ุฉ ุซุงู„ุซุฉ ุจุดุฑูŠ~ ๐ŸŒธ
Download Telegram
Forwarded from ู†ู‚ุงุท ู…ู‡ู…ู‡ ู„ุดูŠุชุงุช ุงู„ุฌุงู…ุนุฉ3ุจุดุฑูŠ ุฏูุนุฉ 47 (Hind Al-Mismari)
73 Mcq -CVS
Forwarded from ู†ู‚ุงุท ู…ู‡ู…ู‡ ู„ุดูŠุชุงุช ุงู„ุฌุงู…ุนุฉ3ุจุดุฑูŠ ุฏูุนุฉ 47 (Hind Al-Mismari)
Case 1
Forwarded from ู†ู‚ุงุท ู…ู‡ู…ู‡ ู„ุดูŠุชุงุช ุงู„ุฌุงู…ุนุฉ3ุจุดุฑูŠ ุฏูุนุฉ 47 (Hind Al-Mismari)
ุฏุงูŠุฑุชู‡ู… ุทุงู„ุจุฉ ู…ู† ุฏูุนุฉ 45

ุถุฑูˆุฑูŠ ุฌุฏุง ุชุญู„ูˆ ูˆุชุฏุฑุจูˆ ุนู„ูŠ cases
ู†ุจุฏูˆุง ุจุงู„ 3) drugs used in heart failure๐Ÿ’ซ

ุงู„ุดูŠุช ูƒู„ุงู…ู‡ ูˆุงุฌุฏ ุจุณ ุชู„ู‚ูˆ ู…ุนุธู…ู‡ ู…ูƒุฑุฑ ูˆ ุฃู‡ู… ุฌุฒุฆูŠุฉ ู‡ูŠ digoxin
โค5
ู‚ุจู„ ู…ุง ู†ุจุฏูˆุง ููŠ ุงู„drugs ู„ุงุฒู… ู†ูู‡ู…ูˆุง ุงู„pathophysiology ู„ู„HF ูˆ ู‡ุฐุง ููŠุฏูŠูˆ ู„ููˆุฏู‡ ุชู„ู‚ูˆ ููŠู‡ ุงู„ุดุฑุญ~ โ˜๏ธ
๐Ÿ‘1
ุฃุญุชู…ุงู„ ูŠุฌู† ุฅูƒุณุจู„ุงูŠู† ุฃูˆ ุดูˆุฑุช ู†ูˆุช~

โ•list drugs used to reduce preload afterload and myocardial contractility in CHF vs AHF? โญ
โ–ซ๏ธCHF
(preload): loop - ACEI ARBs - nitrates
(after load): ACEI ARBs - hydralazine
(contractility): Digoxin

โ–ซ๏ธAHF
(preload): loop - nitrates - nitroprusside
(afterload): nitroprusside
(contractility): dopamine - dobutamine - inamrinone

โ•advantages of ACEI in HF? โญโญโญ
โ–ซ๏ธimprove exercise tolerance & congestive symptoms
โ–ซ๏ธdecrease mortality in HF
โ–ซ๏ธrenoprotective
โ–ซ๏ธdo not induce reflex tachycardia

โญโญโญโ•Explain advantages of ARBs?
โ–ซ๏ธno bradykinin production
โ–ซ๏ธantagonize Ag II formed by ACE
โ–ซ๏ธavoid hormonal escape
โ–ซ๏ธincrease activity of AT2 โ†’ โ†‘VD

โ•List precautions when using nitroprusside?
โ–ซ๏ธgive slow IV
โ–ซ๏ธfreshly prepared in saline with opaque foil
โ–ซ๏ธfrequent monitoring of BP
โ–ซ๏ธavoid prolonged administration to prevent cyanide toxicity

โญโ•Explain the beneficial effects of spironolactone in reducing mortality in HF?

โ•beneficial effects of beta bl. in reducing mortality in HF โญโญโญ
โ–ซ๏ธู†ุฒู„ู‡ ุณู„ุงูŠุฏ

โ•CI of digoxin? โญโญ

โ•Explain why digoxin CI with AF+WPW? โญ
โ–ซ๏ธb/c blocks AVN โ†’ โ†‘conduction in accessory tract

โ•Explain why digoxin CI with erythromycin?
โ–ซ๏ธb/c decrease inactivation of digitalis by killing GIT flora lead to increase absorption and toxicity

โ•Explain digitilization? โญโญโญ
(ู…ู‡ู… ู…ู‡ู… ุฌุฏุง ุงู„ุฏูƒุชูˆุฑุฉ ุนุงูˆุฏุชู‡ุง ูƒู… ู…ุฑุฉ)
โ–ซ๏ธto achieve therapeutic bl. lvl & to avoid toxicity
โ–ซ๏ธlow dose 0.125-0.25 mg/d (Css reached in one week)

โ•TTT of digitalis toxicity? โญโญ

โ•Order of therapy in CHF? โญ
๐Ÿ‘4
ุงู„ุณู„ุงูŠุฏุงุช ุงู„ู„ูŠ ู‚ุงู„ุช ุนู„ูŠู‡ุง ุงู„ุฏูƒุชูˆุฑุฉ ุงู† ู†ุฑูƒุฒูˆุง ุนู„ูŠู‡ ู…ู‡ู…ุงุช ุฌุฏุง๐Ÿ“
๐Ÿ‘2